Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results